Clinical development and informatics analysis of natural and semi-synthetic flavonoid drugs: a critical review

Kuo Xu,Xia Ren,Jintao Wang,Qin Zhang,Xian-Jun Fu,Pei-Cheng Zhang
DOI: https://doi.org/10.1016/j.jare.2023.11.007
IF: 12.822
2023-11-10
Journal of Advanced Research
Abstract:Highlights • This is the most systematic review of flavonoid drugs and clinical candidates to date. • 19 flavonoid drugs are approved for the market, while 36 candidates in clinical phases. • 52.6% of the marketed flavonoid drugs and 44.4% of clinical candidates are natural sources. • 30% of the marketed flavonoid drugs are used for the treatment of cardiovascular diseases. • 50% of the suspended clinical candidates are antineoplastic and immunomodulating agents. • Unexpectedly, flavonoid glycosides account for 36.8% of the marketed flavonoid drugs. Background Flavonoids are one of the most important metabolites with vast structural diversity and a plethora of potential pharmacological applications, which have drawn considerable attention in the laboratory. Nevertheless, it remains uncertain how many candidates were progressed to clinical application. Aim of Review: We carried out a critical review of natural and semi-synthetic flavonoid drugs and candidates undergoing different clinical phases worldwide by applying an adequate search method and conducted a brief cheminformatic and bioinformatic analysis. It was expected that the obtained results might narrow the screening scope and reduce the cost of drug research and development. Key scientific Concepts of Review: To our knowledge, this is the most systematic summarization of flavonoid-based drugs and clinical candidates to date. It was found that a total of 19 flavonoid-based drugs have been approved for the market, and of these, natural flavonoids accounted for 52.6%. Besides, a total of 36 flavonoid-based clinical candidates are undergoing or suspended in different phases, and of these, natural flavonoids account for 44.4%. Thus, natural flavonoids remain the best option for finding novel agents/active templates, and when investigated in conjunction with synthetic chemicals and biologicals, they offer the potential to discover novel structures that can lead to effective agents against a variety of human diseases. Additionally, flavonoid-based marketed drugs have been successful in cardiovascular treatment, and the related drugs account for more than 30% of marketed drugs. However, the use of flavonoids as antineoplastic and immunomodulating agents is not likely for approximately 50% of the candidates suspended in the clinical stage. Interestingly, the marketed drugs covered a broader range of chemical spaces based on size, polarity, and three-dimensional structure compared to the clinical candidates. In addition, flavonoid glycosides with poor oral bioavailability account for 36.8% of the marketed drugs, and thus, they could be thoroughly investigated. Graphical abstract Download : Download high-res image (250KB) Download : Download full-size image
multidisciplinary sciences
What problem does this paper attempt to address?